Synaptogenix Correlations
| SNPX Stock | USD 2.60 0.03 1.17% |
The current 90-days correlation between Synaptogenix and Alzamend Neuro is 0.1 (i.e., Average diversification). The correlation of Synaptogenix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Synaptogenix Correlation With Market
Modest diversification
The correlation between Synaptogenix and DJI is 0.27 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Synaptogenix and DJI in the same portfolio, assuming nothing else is changed.
Synaptogenix |
Moving together with Synaptogenix Stock
| 0.82 | VALN | Valneva SE ADR | PairCorr |
| 0.7 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | IPSC | Century Therapeutics | PairCorr |
| 0.68 | NKTX | Nkarta Inc | PairCorr |
| 0.76 | AGL | agilon health | PairCorr |
| 0.86 | BACK | IMAC Holdings | PairCorr |
| 0.64 | CYRX | Cryoport | PairCorr |
| 0.65 | SHG | Shinhan Financial | PairCorr |
Moving against Synaptogenix Stock
| 0.43 | RNXT | RenovoRx | PairCorr |
| 0.41 | KZR | Kezar Life Sciences | PairCorr |
| 0.35 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.81 | T | ATT Inc Aggressive Push | PairCorr |
| 0.68 | HD | Home Depot | PairCorr |
| 0.65 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.65 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.62 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.56 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.56 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.51 | VFS | VinFast Auto Earnings Call This Week | PairCorr |
| 0.43 | HPQ | HP Inc | PairCorr |
| 0.4 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.38 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.34 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
Related Correlations Analysis
| 0.45 | -0.16 | 0.48 | 0.43 | ANVS | ||
| 0.45 | -0.27 | 0.22 | 0.38 | CYTH | ||
| -0.16 | -0.27 | -0.57 | -0.26 | RVPH | ||
| 0.48 | 0.22 | -0.57 | 0.68 | INMB | ||
| 0.43 | 0.38 | -0.26 | 0.68 | ALZN | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Synaptogenix Stock performing well and Synaptogenix Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Synaptogenix's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ANVS | 3.16 | (0.51) | 0.00 | (0.50) | 0.00 | 6.62 | 20.79 | |||
| CYTH | 3.52 | (0.24) | 0.00 | 5.93 | 0.00 | 5.33 | 25.00 | |||
| RVPH | 4.89 | 0.70 | 0.07 | (0.60) | 5.88 | 10.71 | 38.61 | |||
| INMB | 3.39 | (0.63) | 0.00 | (0.14) | 0.00 | 5.78 | 22.66 | |||
| ALZN | 3.22 | (1.30) | 0.00 | 3.05 | 0.00 | 3.70 | 19.81 |
Synaptogenix Corporate Executives
Elected by the shareholders, the Synaptogenix's board of directors comprises two types of representatives: Synaptogenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synaptogenix. The board's role is to monitor Synaptogenix's management team and ensure that shareholders' interests are well served. Synaptogenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synaptogenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Weinstein | Executive CFO | Profile |